medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2005, Number 2

<< Back Next >>

Rev Mex Patol Clin Med Lab 2005; 52 (2)

Fasciolosis: An actualized clinical-epidemiologic review

Carrada-Bravo T, Escamilla MJR

Language: Spanish
References: 55
Page: 83-96
PDF size: 263.86 Kb.


ABSTRACT

Fasciolosis, a disease of ruminants found worldwide, Fasciola is increasingly being found to be an important human pathogen, especially in the Altiplano of Bolivia and the high plains of Peru and Ecuador, Chile, Argentina, Cuba, Mexico, France and Portugal. It is also hyperendemic in the Nile Delta of Egypt and the North of Iran. Transmission occurs through the ingestion of raw, fresh water or vegetation on which the flukes metacercariae are encysted. Clinical manifestations usually appears within 3-6 weeks of infection, including fever, abdominal pain and eosinophilia. Moreover, parasitologic examination of operculated eggs in feces are often negative in the early hepatic infection. Thus, serologic procedures are important to diagnose the infection. Serodiagnosis is also useful in epidemiologic research to map the presence of human and animal infections. ELISA test and western immunoblot assay using Fasciola hepatica excretion–secretion antigens become positive within two weeks of infection. A stable 26–29 kDa, coproantigen has been isolated and the monoclonal antibodies against this antigen are useful for the detection of the antigen in stools. The new diagnostic armamentarium can be applied to prevention and control efforts of fasciolosis. Triclabendazole is a safe and potent fasciolicide drug.


REFERENCES

  1. Carrada–Bravo T. Fascioliosis. Diagnóstico, epidemiología y tratamientos. Rev Gastroenterol Mex 2003; 68: 135-142.

  2. Atias A. En: Atias A, Neghme A (eds). Parasitología clínica. Buenos Aires, Argentina: Inter–Médica, 1979; 289–295.

  3. Miyazaki I. Fasciolosis. En: Miyazaki I (ed). An Illustrated book of helminthic zoonoses. Tokio: Internat Med Foundation Jap, 1991; 51–60.

  4. Lamothe–Argumedo R. Introducción a la biología de los Platelmintos. México, DF: AGT-Eds, 1983: 83–103.

  5. Biagi F. Fasciolosis. En: Biagi F (ed). Enfermedades Parasitarias. 2a ed. México, DF: Prensa Médica Mexicana, 1988: 219-224.

  6. Acosta–Ferreira W, Vercelli–Retta J, Falconi LM. Fasciola hepatica human infection. Histopathological study of sixteen cases. Virchows Arch A Path Anal Histol 1979; 383: 319–327.

  7. Lamothe–Argumedo R. Helmintiasis del hombre en México, tratamiento y profilaxis. México: AGT–Eds, 1988: 2–131.

  8. Tay ZJ, Lara AR, Velasco CO, Gutiérrez QM. Parasitología médica. 6a ed. México, DF: Méndez–Cervantes, 1998; 483–488.

  9. Sanchez–Vega JT, Tay ZJ, Robert GL. Fascioliosis o Fascioliasis. Rev Fac Med UNAM 1989; 32: 91-98.

  10. Arjona R, Riacho JA, Aguado JM, Salesa R. Fasciolosis in developing countries; a version of classic and aberrant forms of disease. Medicine 1995; 74: 13–23.

  11. Sánchez–Vega JT, Tay-Zavala J, Salinas–Velasco R, Ruíz–Sánchez D, Ordonez–Martínez JJ, Rodríguez–Covarrubias JA. Fasciolosis. Presentación de un caso y revisión de esta trematodiasis. Rev Mex Pediatr 2001; 68: 1720–1724.

  12. Reinhard EG. Landmarks in Parasitology 1. The discovery of the life cycle of the liver fluke. Exp Parasitol 1957; 6: 208–232.

  13. Chatterjee KD. Fasciola hepatica. En: Chatterjee KD (ed). Parasitology (protozoology and helminthology). 10nd ed. Calcutta: SN Guha Ray at Sree Saraswaty Press, 1975; 146–148.

  14. Dan M, Lichtenstein D, Lavochkin J, Stavorowsky M, Jedwab M, Shibolet S. Human fasciolosis in Israel, an imported case. Isr J Med Sci l981; 17: 430–432.

  15. Andrews ST. En: Dalton JP (ed). The life cycle of Fasciola hepatica. Oxon: CAB–International, l999: 1–29.

  16. Catchpole BN, Snow D. Human ectopic fasciolosis. Lancet 1952; 2: 711–712.

  17. Náquira–Vildoso F, Marcial–Rojas RA. Fasciolosis En: Marcial–Rojas RA (ed). Pathology of protozoal and helminthic diseases with clinical correlation. New York; Krieger Pub, 1975: 477–489.

  18. Hillyer GU. Inmunidad contra esquistosomiasis y fasciolosis. Parasitol al Día 1998; 22: 55–62.

  19. Hillyer GU. Improved diagnosis of human fasciolosis. En: Angelico M, Rocchi G (eds). Infections diseases and public health. Filadelfia: Balaban Pub, 1998: 314–324.

  20. Espino AM, Duménigo B, Huesca N, Finlay CM. Mantenimiento in vitro de adultos de Fasciola hepatica obtención de antígenos de excreción–secreción. Rev Salud Animal 1988; 10: 287–293.

  21. Espino AM, Finlay CM. Sandwich enzyme–lynked immunabsorbent assay for the detection excretory–secretory antigens in humans with fasciolosis. J Clin Microbiol 1994; 32 190–193.

  22. Dumenigo BE, Espino AM, Finlay CM. Detection of Fasciola hepatica antigen in castle faeces by monoclonal antibody–based sandwich immunoassay. Res Vet Sci 1996; 60: 278–279.

  23. Díaz A L, Elías O, Otero O, García C, Espino AM. Identificación, mediante Western Blot, de inmunógenos de Fasciola hepatica, reconocidos por los sueros de ratas infectadas experimentalmente. Rev Cubana Med Trop 1998; 50: 12–17.

  24. Espino AM, Borges A, Duménigo BE. Coproantígenos de Fasciola hepatica de posible utilidad en el diagnóstico de la fascioliasis. Rev Panam Sal Pub 2000; 7: 225–231.

  25. O’ Nelly SM, Parkinson M, Strauss W, Angles R, Dalton JP. Immunodiagnosis of Fasciola hepatica (fascioliosis) in human population in the Bolivian Altiplano using purified cathepsin L–cysteine proteinase. Am J Trop Med Hyg 1998; 58: 417–423.

  26. Smith WD. Prospects for vaccines of helminth parasites of grazing ruminants. Int J Parasitol 1999; 29: 17–24.

  27. Behm CA. Pathophysiology of Fasciola hepatica infections in mammals. In: Boray JC (ed). Immunology, pathology and control of fasciolosis. Izmir: MSD–AGVET ed, 1994: 1–214.

  28. Mas–Coma S, Bargues MD. Human liver flukes: a review. Res Rev Parasitol 1997; 57: 145–218.

  29. Mas–Coma S, Bargues MD, Valero MA, Fuentes MV. Adaptation capacities of Fasciola hepatica and their relationships with human fasciolosis: from below sea level up to the very high altitude. In: Combos C, Jourdane J (eds). Taxonomy, ecology and evolution of metazoar parasites. Perpignan, Francia: 2003: 81–123.

  30. Mas–Coma MS, Esteban JG, Bargues MD. Epidemiología de la fasciolosis humana: Revisión y propuesta de nueva clasificación. Bull WHO 1999; 77: 340–346.

  31. Rondeland D, Dreyfuss G, Bouteille B, Darde ML. Changes in human fasciolosis in a temperate area: about some observation over a 28 year period in central France. Parasitol Res 2000; 86: 753–757.

  32. Mc Carthy J, Moore TA. Emerging helminth zoonoses. Int J Parasitol 2000; 30: 1351–1360.

  33. Togerson P, Claxtan J. In: Dalton JP (ed). Epidemiology and control. Oxon: CAB–International, 1999: 113–149.

  34. Rim HJ, Farcy HF, Sornmani S, Cross JH. Food–borne trematodes: Ignored or emerging? Parasitology Today 1994; 10: 207–209.

  35. Hopkins DR. Homing in on helminths. Am J Trop Med Hyg 1992; 46: 626–634.

  36. Mas–Coma S. In: Angelico M (ed). Human fasciolosis in Europe and Latin America. Rehovor, Israel: Balaban Pub, 1998: 1–17.

  37. OMS. Control of foodborne trematode infections. Ginebra: Pub OMS 1995 (Tech Rep Ser 849).

  38. Chen MG, Mott KE. Progress in assessment of morbidity due to Fasciola hepatica infection: A review of recent literature. Trop Dis Bull 1990; 87: R2–R28.

  39. Marcus–Raymundo LA, Maco-Flores V, Terashima A, Samalvides F, Miranda E, Tantalean M et al. Hiperendemicidad de Fascioliosis humana en el Valle de Mantaro, Perú: Factores de riesgo de la infección por Fasciola hepatica. Rev Gastroenterol Peru 2004; 24: 36–42.

  40. Hurtrez Obuses S, Meunier C, Dusand P, Renaud F. Dynamic of host–parasite interactions: The example of population biology of the liver fluke (Fasciola hepatica). Microbes Infect 2001; 3: 841–849.

  41. Mas–Comas S, Angles R, Esteban JG, Bargues MD, Buchon P, Franken M et al. The Northen Bolivian Altiplano: A region of high endemicity for human fascioliosis. Trop Med Int Health 1999; 4: 454–467.

  42. Esteban JG, Bargues MD, Mas–Comas S. High endemicity of human fasciolosis between Lake Titicaca and la Paz Valley, Bolivia. Trans R Soc Trop Med Hyg 1999; 93: 151–156.

  43. Faray HF. Human fasciolosis in some countries of the Eastern Mediterranean Region. Eastern Mediterranean Health J 1998; 4: 156-160.

  44. Stark ME, Herrington DA, Hillyer GU, Mc Gill DB. An International Traveler with Fever, Abdominal pain, Eosinofilia, and a liver lesion. Gastroenterology 1993; 105: 1900–1908.

  45. Case Records of the Massachusetts General Hospital (Case 12–2002). N Engl J Med 20002; 346: 1232–1238.

  46. Jones EA, Kay JM, Milligan HP, Owens D. Massive infection with Fasciola hepatica in man. Am J Med 1977; 63: 836–842.

  47. Cosme A, Ojeda E, Cilla G. Fasciola hepatica. Study of a series of 37 patients. Gatroenterol Hepatol 2001; 24: 375–380.

  48. Apt W, Tisley R. Fasciolosis hepática: diagnóstico por colangiopancreatografía endoscópica retrógrada. Rev Med Chile 1987; 115: 564-568.

  49. Martínez R, Ruiz J, Díaz O. The diagnosis of fasciolosis of biliary tract by imaging. Rev Cubana Med Trop 2000; 52: 145-147.

  50. Velásquez García JA, Arrubena Aragón VM, Fenig Rodríguez J. Fasciola hepatica como causa de obstrucción biliar. Informe de un paciente. Cir Gen (Mex) 1992; 14: 112-115.

  51. Hillyer GV, Apt W. Food borne trematode infections in the Americas. Parasitol Today 1997; 13: 87–88.

  52. El Morshed YH, Shehab AY, Farag HF. Intra specimen and day to day variations of Fasciola eggs counts in human stools. Eastern Mediterranean Health J 2002; 8: 9-15.

  53. Akahane H, Oshima T, Shimazu T, Hisroshima K. Diagnosis of fasciolosis I. Comparison of efficacies of variuos concentrations techniques of ova in stool. Jpn J Parasitol 1975; 24: 55-60.

  54. El Morshedy H, Farghaly A, Sharaf S, Abou Basha L, Barakat R. Triclabendazole in the treatment of human fasciolosis: community based study. Eastern Mediterranean Health J 1999; 5: 888-894.

  55. Apt W, Aguilera X, Vega F. Treatment of human chronic fasciolosis with triclabendazole: drug efficacy and serologic response. Am J Trop Med Hyg 1995; 52: 532–535.




2020     |     www.medigraphic.com